Portal hypertension and liver lesions in chronically alcohol drinking rats prevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine.
Liver lesions and portal hypertension in rats, following chronic alcohol administration, are a particular target for therapy. Portal hypertension (mm Hg) assessed directly into the portal vein, and liver lesions induced by 7.28 g/kg b.w. of alcohol given in drinking water for 3 months, were counteracted by a stable gastric pentadecapeptide BPC 157, GEPPPGKPADDAGLV, M.W. 1419, known to have a beneficial effect in a variety of models of gastrointestinal or liver lesions (10 microg or 10 ng/kg b.w. i.p. or i.g.) and propranolol (10 mg/kg b.w. i.g.), but not ranitidine (10 mg/kg b.w. i.g.) or saline (5 ml/kg b.w. i.p./i.g.; control). The medication (once daily) was throughout either the whole 3 months period (1) or the last month only (2) (last application 24 h before sacrifice). In the background of 7.28 g/kg/daily alcohol regimen similar lesions values were assessed in control rats following alcohol consumption, after 2 or 3 months of drinking. Both prophylactic and therapeutic effects were shown. After a period of 2 or 3 months, in all control saline [intragastrically (i.g.) or intraperitoneally (i.p.)] treated rats, the applied alcohol regimen consistently induced a significant rise of portal blood pressure values over values noted in healthy rats. In rats that received gastric pentadecapeptide BPC 157 or propranolol the otherwise raised portal pressure was reduced to the values noted in healthy rats. Besides, a raised surface area (microm(2)) and increased circumference (microm) of hepatocyte or hepatocyte nucleus [HE staining, measured using PC-compatible program ISSA (VAMS, Zagreb, Croatia)] and an advanced steatosis [scored (0-4), Oil Red staining] (on 100 randomly assigned hepatocytes per each liver), an increased liver weight, all together parallel a raised portal pressure in controls. Some of them were completely eliminated (not different from healthy rats, i.e. portal pressure, the circumference and area of hepatocytes, liver weight), while others were markedly attenuated (values less than in drinking controls, still higher than in healthy rats, i.e. circumference and area of hepatocytes nucleus). On the other hand, ranitidine application attenuated only steatosis development. In summary, despite continuous chronic alcohol drinking, pentadecapeptide BPC 157, and propranolol may prevent portal hypertension as well as reverse already established portal hypertension along with related liver disturbances.
Prkacin
I
I
Department of Pharmacology, Medical Faculty University of Zagreb, Salata 11, PO Box 916, 10000, Zagreb, Croatia
Separovic
J
J
Aralicia
G
G
Perovic
D
D
Gjurasin
M
M
Lovric-Bencic
M
M
Stancic-Rokotov
D
D
Staresinic
M
M
Anic
T
T
Mikus
D
D
Sikiric
P
P
Seiwerth
S
S
Mise
S
S
Rotkvic
I
I
Jagic
V
V
Rucman
R
R
Petek
M
M
Turkovic
B
B
Marovic
A
A
Sebecic
B
B
Boban-Blagaic
A
A
Kokic
N
N
D000428:Alcohol Drinking; D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D006975:Hypertension, Portal / Q000188:drug therapy / Q000517:prevention & control*; D008108:Liver Diseases, Alcoholic / Q000188:drug therapy / Q000517:prevention & control*; D008297:Male; D010446:Peptide Fragments / Q000627:therapeutic use*; D011433:Propranolol / Q000627:therapeutic use*; D011506:Proteins / Q000627:therapeutic use*; D011899:Ranitidine / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar
D000959:Antihypertensive Agents; D010446:Peptide Fragments; D011506:Proteins; D011899:Ranitidine; C083833:BPC 157; D011433:Propranolol